MBOT

Microbot Medical Inc. (MBOT) ESG Analysis Analysis (2026)

Invetso Score: 6.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 6.4 (Moderate)

MBOT’s high R&D intensity supports a lower-operating-footprint innovation model versus peers with heavier manufacturing or logistics emissions exposure.

The company’s very low leverage reduces balance-sheet pressure that can otherwise constrain environmental capex, but peer comparison is limited by sparse disclosure.

Negative gross margin suggests the current operating model is not yet structurally efficient, which can delay scaling of resource-use improvements versus better-established peers.

No post-August 2025 filing evidence was provided on energy use, emissions, or waste, so environmental positioning remains harder to verify than for more transparent peers.

Social

Score:

MBOT’s elevated R&D spend indicates a workforce centered on technical development, which can support higher-skill employment quality versus peers with more routine labor exposure.

Low stock-based compensation relative to revenue suggests less dilution-linked employee cost pressure than many early-stage peers, supporting a cleaner compensation profile.

However, the absence of provided disclosure on safety, turnover, diversity, or customer-impact metrics limits confidence that social practices are stronger than peers.

The company’s small scale likely concentrates key-person and execution risk, which can make social resilience less robust than at larger, more diversified peers.

Governance

Score:

Very low debt-to-equity indicates conservative capital structure discipline, which reduces creditor pressure and governance strain relative to more levered peers.

Low net debt to EBITDA further supports financial flexibility, lowering the likelihood that governance decisions are distorted by refinancing or covenant risk.

Stock-based compensation at a modest level versus revenue suggests comparatively restrained dilution, which is generally more shareholder-aligned than aggressive peer practices.

Limited provided disclosure on board independence, audit oversight, and shareholder rights prevents a higher score, but no major governance red flags were evident.

Overall Score

Score:

MBOT’s ESG positioning is mixed, with relatively stronger governance and technical-workforce characteristics offset by limited disclosure and an unproven operating footprint versus peers.

Score Driver: Conservative Leverage And Restrained Compensation Practices Are The Clearest Relative Strengths, While Sparse ESG Disclosure Caps The Overall Assessment.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Microbot Medical Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →